Intervention

fludarabine phosphate

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 8 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials8

Recruiting0

Common conditions25

Lead sponsors shown7

Clinical trials

8 shown

Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With CancerNCT01212887 · 2007-08-01

TERMINATED

Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast CancerNCT00074269 · 2003-07-01

TERMINATED

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast CancerNCT00048893 · 2002-11-01

TERMINATED

Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney CancerNCT00365287 · 2000-06-01

COMPLETED

Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast CancerNCT00020176 · 2000-06-01

COMPLETED

Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast CancerNCT00006261 · 2000-05-01

WITHDRAWN

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerNCT00112593 · 1999-11-01

COMPLETED

Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With SurgeryNCT00006126 · 1999-09-01

WITHDRAWN

Common conditions

Breast Cancer6 Kidney Cancer2 Lung Cancer2 Unspecified Adult Solid Tumor, Protocol Specific2 Accelerated Phase Chronic Myelogenous Leukemia1 Acute Undifferentiated Leukemia1 Adult Acute Lymphoblastic Leukemia in Remission1 Adult Acute Myeloid Leukemia in Remission1 Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities1 Adult Acute Myeloid Leukemia With Del(5q)1 Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)1 Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)1 Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)1 Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)1 Adult Grade III Lymphomatoid Granulomatosis1 Adult Nasal Type Extranodal NK/T-cell Lymphoma1 Aggressive NK-cell Leukemia1 AIDS-related Diffuse Large Cell Lymphoma1 AIDS-related Diffuse Mixed Cell Lymphoma1 AIDS-related Diffuse Small Cleaved Cell Lymphoma1 AIDS-related Immunoblastic Large Cell Lymphoma1 AIDS-related Lymphoblastic Lymphoma1 AIDS-related Peripheral/Systemic Lymphoma1 AIDS-related Primary CNS Lymphoma1 AIDS-related Small Noncleaved Cell Lymphoma1

Leading sponsors

National Cancer Institute (NCI) 2 Cancer Research UK 1 Case Comprehensive Cancer Center 1 Fred Hutchinson Cancer Center 1 Masonic Cancer Center, University of Minnesota 1 Northwestern University 1 University of California, San Diego 1

Trial status mix

COMPLETED3

TERMINATED3

WITHDRAWN2

Phase mix

PHASE25

PHASE14

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.